Krebs Biochem

Why is Krebs Biochemicals & Industries Ltd falling/rising?

As of 06-Aug, Krebs Biochemicals & Industries Ltd's stock price is Rs 53.49, reflecting a decline of -1.36%. The stock has shown significant volatility and negative performance, with a year-to-date drop of -23.19% and declining investor participation.

As of 06-Aug, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 53.49, which reflects a change of -0.74 (-1.36%). The stock has shown a negative performance over various time frames, with a year-to-date decline of -23.19% and a one-year drop of -33.02%. <BR><BR>Today, the stock opened with a loss of -3.72% and has traded within a wide range, hitting a high of Rs 57.85 and a low of Rs 52.21. This indicates significant volatility, with an intraday volatility of 5.82%. Additionally, the stock's performance has been erratic, as it did not trade on one day out of the last 20 days. <BR><BR>Investor participation appears to be falling, as evidenced by a delivery volume of 1.95k on 05 Aug, which is down by -69.19% compared to the 5-day average. This decline in trading activity may contribute to the stock's downward pressure. Furthermore, while the stock has outperformed its sector by 1.97% today, the overall trend remains negative, with the stock trading below its longer-term moving averages (50-day, 100-day, and 200-day), indicating a bearish sentiment among investors.

Which are the latest news on Krebs Biochem?

How big is Krebs Biochem?

As of 10th June, Krebs Biochemicals & Industries Ltd has a market capitalization of 146.00 Cr and reported Net Sales of 23.73 Cr with a Net Profit loss of 16.93 Cr over the latest four quarters.

As of 10th June, Krebs Biochemicals & Industries Ltd has a market capitalization of 146.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Krebs Biochem reported Net Sales of 23.73 Cr. However, the company experienced a loss of 16.93 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. At that time, Shareholder's Funds stood at a loss of 146.24 Cr, while Total Assets were valued at 169.04 Cr.

Who are in the management team of Krebs Biochem?

The management team of Krebs Biochem includes G V L Prasad (Independent Director), R T Ravi (Chairman), Avinash Ravi (Non-Executive Director), Tangirala Malati, Satish Khivsara, Raj Kamal Prasad Verma (all Independent Directors), Rohit Taparia (Company Secretary), and Jitendra Shah (Managing Director).

The management team of Krebs Biochem includes the following members:<BR><BR>1. **G V L Prasad** - Independent Director<BR>2. **R T Ravi** - Chairman (Non-Executive)<BR>3. **Avinash Ravi** - Non-Executive Director<BR>4. **Tangirala Malati** - Independent Director<BR>5. **Satish Khivsara** - Independent Director<BR>6. **Raj Kamal Prasad Verma** - Independent Director<BR>7. **Rohit Taparia** - Company Secretary & Compliance Officer<BR>8. **Jitendra Shah** - Managing Director<BR><BR>If you have any more questions about Krebs Biochem or its management, feel free to ask!

Who are the peers of the Krebs Biochem?

Krebs Biochem's peers include Kimia Bioscien., Achyut Healthcar, Auro Labs., Parnax Lab, Alpa Laboratorie, Bal Pharma, Smruthi Organic, Lactose (India), and Accretion Pha. Achyut Healthcar has the highest 1-year return at 71.17%, while Krebs Biochem has the lowest at -29.43%.

Peers: The peers of Krebs Biochem are Kimia Bioscien., Achyut Healthcar, Auro Labs., Parnax Lab, Alpa Laboratorie, Bal Pharma, Smruthi Organic, Lactose (India), and Accretion Pha.<BR><BR>Quality Snapshot: Below Average management risk is observed at Kimia Bioscien., Achyut Healthcar, Auro Labs., and the rest. Average management risk is found at Alpa Laboratorie, Bal Pharma, Smruthi Organic, and the rest. Excellent capital structure is noted at Parnax Lab and Alpa Laboratorie, while Good capital structure is seen at Achyut Healthcar and Smruthi Organic, with the rest having Below Average or not qualifying.<BR><BR>Return Snapshot: Achyut Healthcar has the highest 1-year return at 71.17%, while Krebs Biochem has the lowest at -29.43%. Krebs Biochem's return is significantly lower than Achyut Healthcar's. Additionally, the six-month returns are negative for Krebs Biochem, Alpa Laboratorie, Smruthi Organic, and Lactose (India).

What does Krebs Biochem do?

Krebs Biochemicals & Industries Ltd manufactures Active Pharmaceutical Ingredients (API) through fermentation and operates in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 7 Cr and a net loss of 2 Cr, with a market cap of INR 146 Cr.

Overview: <BR>Krebs Biochemicals & Industries Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API) through a fermentation process, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1991 and promoted by R T Ravi, Krebs Biochemicals & Industries Ltd was formerly known as Krebs Biochemicals Ltd. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 146 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.38 <BR>Return on Equity: 10.40% <BR>Price to Book: -0.90<BR><BR>Contact Details: <BR>Address: Kothapalli(V) Kasimkota(M), Anakapalli Vishakapatnam Andhra Pradesh : 531031 <BR>Tel: 91-040-6680 8040 <BR>Email: investors@kerbsbiochem.com <BR>Website: http://www.krebsbiochem.com

Are Krebs Biochemicals & Industries Ltd latest results good or bad?

Krebs Biochemicals & Industries Ltd's latest results are concerning, showing a net loss of ₹2.34 crores and ongoing operational challenges, despite a slight increase in net sales. The company has negative equity and has recorded losses for seven consecutive quarters, indicating a struggling financial position.

Krebs Biochemicals & Industries Ltd's latest results indicate a challenging financial situation. In the fourth quarter of FY26, the company reported a net loss of ₹2.34 crores, which, while an improvement of 25.24% from the previous quarter, is still significantly worse than the loss of ₹8.27 crores in the same quarter last year. The company's net sales of ₹6.81 crores showed a modest year-on-year growth of 11.64%, but this was accompanied by a sequential decline of 6.33% from the previous quarter.<BR><BR>The company's financial health is concerning, highlighted by a negative book value of ₹-67.83 per share and a persistent negative PAT margin of -34.36%. This reflects ongoing operational challenges and a lack of profitability, as the company has recorded losses for seven consecutive quarters. Additionally, the cash burn remains significant, with negative cash flow from operations reported in four of the last five years.<BR><BR>Overall, while there are some signs of improvement in sales growth, the fundamental issues of negative equity, persistent losses, and operational instability suggest that the results are more indicative of a struggling business rather than a turnaround. Investors should approach this company with caution given the current financial metrics and outlook.

When is the next results date for Krebs Biochemicals & Industries Ltd?

The next results date for Krebs Biochemicals & Industries Ltd is 21 May 2026.

The next results date for Krebs Biochemicals & Industries Ltd is scheduled for 21 May 2026.

How has been the historical performance of Krebs Biochem?

Krebs Biochem has experienced declining net sales and increasing losses, with total operating income falling from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25, and negative operating profit worsening from -33.99 Cr to -14.32 Cr during the same period. The company's financial health is further indicated by rising total liabilities and deteriorating shareholder equity, resulting in ongoing financial challenges.

Answer:<BR>The historical performance of Krebs Biochem shows a trend of declining net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Krebs Biochem's net sales decreased from 52.94 Cr in Mar'22 to 43.31 Cr in Mar'25, reflecting a downward trend. Other operating income, which was 6.76 Cr in Mar'22, has dropped to zero by Mar'25, contributing to a total operating income decline from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25. The total expenditure, excluding depreciation, has also decreased from 93.69 Cr in Mar'22 to 58.34 Cr in Mar'25. However, the operating profit (PBDIT) remains negative, worsening from -33.99 Cr in Mar'22 to -14.32 Cr in Mar'25. The profit before tax and profit after tax have shown similar negative trends, with losses increasing from -44.53 Cr and -44.53 Cr in Mar'22 to -26.92 Cr and -26.94 Cr in Mar'25, respectively. The company's total liabilities have increased from 159.22 Cr in Mar'21 to 169.04 Cr in Mar'25, while shareholder's funds have deteriorated, showing a negative value of -146.24 Cr in Mar'25. The cash flow from operating activities has remained negative, indicating ongoing financial challenges. Overall, Krebs Biochem's financial performance has been characterized by declining revenues, increasing losses, and deteriorating equity over the years.

What is the technical trend for Krebs Biochem?

As of June 6, 2025, Krebs Biochem's technical trend has shifted to mildly bullish, supported by positive weekly MACD, KST, and Bollinger Bands, although daily moving averages suggest caution.

As of 6 June 2025, the technical trend for Krebs Biochem has changed from mildly bearish to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting the positive shift in sentiment. The Bollinger Bands are also indicating a bullish stance on both weekly and monthly time frames. However, the daily moving averages remain mildly bearish, which suggests some caution. The Dow Theory shows a mixed signal with a mildly bullish weekly stance but a mildly bearish monthly outlook. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Bollinger Bands.

Who are the top shareholders of the Krebs Biochem?

The top shareholders of Krebs Biochem are Ipca Laboratories Limited, holding 49.65%, and Sun Pharmaceutical Industries Ltd, the largest public shareholder with 4.81%. Individual investors own 20.42%, while foreign institutional investors hold 0.5%, and there are no mutual funds invested in the company.

The top shareholders of Krebs Biochem include its majority shareholders, who are the promoters. The promoter with the highest holding is Ipca Laboratories Limited, which owns 49.65% of the company. Additionally, Sun Pharmaceutical Industries Ltd is the highest public shareholder, holding 4.81%. Individual investors collectively hold 20.42% of the shares, while foreign institutional investors (FIIs) hold 0.5% through five different FIIs. There are no mutual funds currently invested in Krebs Biochem.

Has Krebs Biochem declared dividend?

No Dividend History Available

Should I buy, sell or hold Krebs Biochem?